'Potential Blockbuster' Dupixent Set For EU Eczema OK
While Dupixent looks set for use in Europe for treating moderate-to-severe atopic dermatitis, analysts believe the biologic has a great future in other indications and could eventually become a blockbuster.
You may also be interested in...
Significant shifts in innovation for atopic dermatitis are behind the decision to close down the current R&D center of Nestlé group prescription dermatology business Galderma. The move affects around 550 employees in Sophia Antipolis, France, with only a small proportion likely to be offered jobs in a planned new center of excellence.
Regeneron and Sanofi have decided to call it a day on their antibody discovery partnership that brought the world Praluent, Dupixent and Kevzara. Regeneron announced that the collaboration was winding down during its Q2 results, where investors were focused on Dupixent's launch progress.
No surprises from Sanofi in the second quarter as sales of its flagship diabetes drug continue to fall – but a strong performance from recently launched Dupixent provided the French pharma with a refreshing reprieve in its earnings update.